HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Why treat early multiple sclerosis patients?

Abstract
Class 1 clinical trials demonstrated that immunomodulatory treatments (interferon beta and glatiramer acetate) reduce the disease activity and the accumulation of disability in relapsing remitting multiple sclerosis. Moreover interferon beta-1b also had similar positive effects in secondary progressive multiple sclerosis. The magnitude of these clinical effects was modest, but the reduction of inflammatory activity, as revealed by magnetic resonance imaging, was marked. Converging evidence from new pathological studies and new magnetic resonance techniques, characterized by increased pathological specificity, has shown that already in the early phases of the disease inflammatory activity determines irreversible axonal damage. Moreover, the amount of inflammatory activity at the clinical presentation of the disease has some value in predicting long-term disability. Taken together, these data indicate that patients may benefit from early treatment; the positive results of the Controlled High Risk Subjects Avonex Multiple Sclerosis Prevention Study support this conclusion.
AuthorsG Comi
JournalCurrent opinion in neurology (Curr Opin Neurol) Vol. 13 Issue 3 Pg. 235-40 (Jun 2000) ISSN: 1350-7540 [Print] England
PMID10871245 (Publication Type: Editorial, Review)
Chemical References
  • Adjuvants, Immunologic
  • Peptides
  • Glatiramer Acetate
  • Interferon-beta
Topics
  • Adjuvants, Immunologic (therapeutic use)
  • Glatiramer Acetate
  • Humans
  • Interferon-beta (therapeutic use)
  • Multiple Sclerosis (drug therapy)
  • Peptides (therapeutic use)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: